Jane Street
KTTA icon

Jane Street’s Pasithea Therapeutics KTTA Stock Holding History

Jane Street’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-59,372
Closed -$76.6K – 12337
2025
Q4 		$76.6K Buy
59,372
+34,319
+137% +$30.2K ﹤0.01% 10327
2025
Q3 		$18.3K Buy
+25,053
New +$18.3K ﹤0.01% 10544
2024
Q1 		– Sell
-1,179
Closed -$8.73K – 9681
2023
Q4 		$8.73K Buy
+1,179
New +$8.74K ﹤0.01% 8977
2023
Q3 		– Sell
-743
Closed -$7.28K – 9041
2023
Q2 		$7.28K Buy
+743
New +$5.99K ﹤0.01% 8468

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street's KTTA Position: Q1 2026 in Review

Jane Street sold out of Pasithea Therapeutics (KTTA) in Q1 2026, closing a stake of 59,372 shares — an estimated $76.6K sold.

Jane Street first reported a position in KTTA in Q2 2023 and held it in 4 quarters. The position peaked at $76.6K in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Jane Street reported no remaining Pasithea Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 59,372 Pasithea Therapeutics shares in Q1 2026, an estimated $76.6K.
  • Jane Street first reported a position in Pasithea Therapeutics in Q2 2023 and held it in 4 quarters.
  • Jane Street's Pasithea Therapeutics position peaked at $76.6K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.